Source comparison
Substrate Oxidation Shifts: Glucose vs Lipid Utilization in MK-677 Research Models
One of the most cited metabolic effects of MK-677 is its impact on substrate oxidation. Specifically, the preferential shift toward lipid oxidation during fasting states. A randomized controlled trial conducted at the Mayo Clinic measured respiratory quotient
This comparison does not assign a generated winner or score.
- One of the most cited metabolic effects of MK-677 is its impact on substrate oxidation. Specifically, the preferential shift toward lipid oxidation during fasting states. A randomized controlled trial conducted at the Mayo Clinic measured respiratory quotient (RQ) in healthy older adults before and after 8 weeks of 25mg daily MK-677. Fasting RQ decreased from 0.83 to 0.76, indicating a shift from mixed carbohydrate-fat oxidation (RQ ~0.85) toward predominantly fat oxidation (RQ <0.78). This shift was most pronounced during overnight fasting (8–12 hours post-meal), when GH levels peak naturally and lipolysis is highest.
- The mechanism involves GH-mediated activation of hormone-sensitive lipase (HSL) in adipocytes, which cleaves stored triglycerides into free fatty acids and glycerol. These free fatty acids are then transported to mitochondria via carnitine palmitoyltransferase-I (CPT-I) for beta-oxidation. GH directly increases CPT-I expression in skeletal muscle and liver tissue, enhancing the cell's capacity to oxidize fat rather than store it. However. And this is where most discussions fail. This effect is entirely dependent on baseline insulin sensitivity. In insulin-resistant subjects, elevated insulin blocks HSL activation even in the presence of elevated GH, preventing lipolysis and nullifying the fat oxidation benefit.
- A 2019 study published in Obesity Research & Clinical Practice divided participants into insulin-sensitive (HOMA-IR <2.0) and insulin-resistant (HOMA-IR >3.5) groups, then administered 25mg MK-677 daily for 12 weeks. Insulin-sensitive subjects experienced mean fat mass reduction of 1.4 kg with no change in lean mass. Insulin-resistant subjects showed no significant change in fat mass despite identical GH and IGF-1 elevation. The difference was substrate partitioning: insulin-resistant subjects oxidized carbohydrates at the same rate as baseline, while insulin-sensitive subjects shifted to predominantly fat oxidation during fasting. This finding underscores a critical reality that marketing claims ignore. MK-677 does not override poor metabolic health. It amplifies existing substrate utilization patterns.